Home/Filings/4/0000950170-24-011501
4//SEC Filing

Keutzer Timothy 4

Accession 0000950170-24-011501

CIK 0001701108other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 8:53 PM ET

Size

7.1 KB

Accession

0000950170-24-011501

Insider Transaction Report

Form 4
Period: 2024-02-01
Keutzer Timothy
Chief Operating Officer
Transactions
  • Award

    Common Stock

    2024-02-01+239,731565,021 total
  • Sale

    Common Stock

    2024-02-02$1.36/sh30,971$42,121534,050 total
Footnotes (3)
  • [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
  • [F2]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement.
  • [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Documents

1 file

Issuer

Spero Therapeutics, Inc.

CIK 0001701108

Entity typeother

Related Parties

1
  • filerCIK 0001798155

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:53 PM ET
Size
7.1 KB